Werba Rubin Papier Wealth Management Purchases New Position in Intuitive Surgical, Inc. (NASDAQ:ISRG)

Werba Rubin Papier Wealth Management acquired a new stake in Intuitive Surgical, Inc. (NASDAQ:ISRG) during the 2nd quarter, according to its most recent disclosure with the SEC. The institutional investor acquired 508 shares of the medical equipment provider’s stock, valued at approximately $226,000.

Other institutional investors have also added to or reduced their stakes in the company. Ballentine Partners LLC raised its position in Intuitive Surgical by 6.6% in the 2nd quarter. Ballentine Partners LLC now owns 3,451 shares of the medical equipment provider’s stock worth $1,535,000 after buying an additional 215 shares during the last quarter. Caprock Group LLC increased its position in Intuitive Surgical by 37.8% during the second quarter. Caprock Group LLC now owns 7,516 shares of the medical equipment provider’s stock valued at $3,344,000 after acquiring an additional 2,061 shares during the last quarter. Custom Index Systems LLC lifted its holdings in Intuitive Surgical by 20.8% in the second quarter. Custom Index Systems LLC now owns 818 shares of the medical equipment provider’s stock valued at $364,000 after acquiring an additional 141 shares during the period. Acadian Asset Management LLC grew its stake in shares of Intuitive Surgical by 19.9% during the 2nd quarter. Acadian Asset Management LLC now owns 24,197 shares of the medical equipment provider’s stock valued at $10,760,000 after purchasing an additional 4,009 shares during the period. Finally, Asset Dedication LLC raised its position in Intuitive Surgical by 320.0% in the second quarter. Asset Dedication LLC now owns 231 shares of the medical equipment provider’s stock worth $103,000 after acquiring an additional 176 shares during the period. 83.64% of the stock is currently owned by hedge funds and other institutional investors.

Intuitive Surgical Stock Performance

Shares of ISRG traded down $4.87 during trading hours on Friday, hitting $471.82. The stock had a trading volume of 1,700,169 shares, compared to its average volume of 1,518,588. The firm has a 50-day moving average price of $458.74 and a 200 day moving average price of $418.27. Intuitive Surgical, Inc. has a fifty-two week low of $254.85 and a fifty-two week high of $493.97. The firm has a market capitalization of $167.35 billion, a price-to-earnings ratio of 85.17, a PEG ratio of 5.43 and a beta of 1.39.

Intuitive Surgical (NASDAQ:ISRG) last posted its earnings results on Thursday, July 18th. The medical equipment provider reported $1.78 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.54 by $0.24. The business had revenue of $2.01 billion for the quarter, compared to analyst estimates of $1.97 billion. Intuitive Surgical had a net margin of 27.65% and a return on equity of 13.04%. The company’s revenue for the quarter was up 14.5% on a year-over-year basis. During the same period in the prior year, the company posted $1.18 EPS. As a group, analysts predict that Intuitive Surgical, Inc. will post 5.22 EPS for the current fiscal year.

Analysts Set New Price Targets

Several research firms recently issued reports on ISRG. Truist Financial increased their target price on shares of Intuitive Surgical from $450.00 to $515.00 and gave the stock a “buy” rating in a report on Tuesday, July 16th. JPMorgan Chase & Co. boosted their target price on Intuitive Surgical from $475.00 to $495.00 and gave the stock an “overweight” rating in a research report on Friday, July 19th. Redburn Atlantic upgraded shares of Intuitive Surgical from a “neutral” rating to a “buy” rating and boosted their price target for the stock from $380.00 to $510.00 in a research report on Friday, August 2nd. Morgan Stanley increased their price target on shares of Intuitive Surgical from $375.00 to $460.00 and gave the company an “equal weight” rating in a report on Monday, July 15th. Finally, Stifel Nicolaus boosted their price objective on Intuitive Surgical from $430.00 to $475.00 and gave the stock a “buy” rating in a research note on Friday, July 19th. Six research analysts have rated the stock with a hold rating and fifteen have issued a buy rating to the company’s stock. According to data from MarketBeat, the company has an average rating of “Moderate Buy” and an average target price of $446.45.

Insider Transactions at Intuitive Surgical

In other news, EVP Robert Desantis sold 188 shares of the firm’s stock in a transaction that occurred on Thursday, August 29th. The stock was sold at an average price of $482.21, for a total value of $90,655.48. Following the transaction, the executive vice president now owns 5,506 shares in the company, valued at $2,655,048.26. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. In related news, EVP Robert Desantis sold 188 shares of the company’s stock in a transaction dated Thursday, August 29th. The shares were sold at an average price of $482.21, for a total transaction of $90,655.48. Following the completion of the sale, the executive vice president now owns 5,506 shares of the company’s stock, valued at approximately $2,655,048.26. The sale was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Also, SVP Henry L. Charlton sold 40,243 shares of the firm’s stock in a transaction that occurred on Friday, August 23rd. The stock was sold at an average price of $486.84, for a total transaction of $19,591,902.12. Following the completion of the transaction, the senior vice president now directly owns 3,001 shares in the company, valued at $1,461,006.84. The disclosure for this sale can be found here. Insiders sold 51,656 shares of company stock valued at $24,700,644 over the last 90 days. Corporate insiders own 0.90% of the company’s stock.

Intuitive Surgical Profile

Intuitive Surgical, Inc develops, manufactures, and markets products that enable physicians and healthcare providers to enhance the quality of and access to minimally invasive care in the United States and internationally. The company offers the da Vinci Surgical System that enables complex surgery using a minimally invasive approach; and Ion endoluminal system, which extends its commercial offerings beyond surgery into diagnostic procedures enabling minimally invasive biopsies in the lung.